RTGN
RetinalGenix Technologies Inc.3.2000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
59.54MP/E (TTM)
-Basic EPS (TTM)
-0.15Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
RetinalGenix narrowed its Q2 net loss to $649K from $664K a year earlier, while YTD losses eased to $1.2M from $2.8M, thanks to R&D costs plunging 83% y/y to $14K amid funding constraints. Total operating expenses dipped 2% y/y to $648K, driven by lower engineering and pilot manufacturing, yet stock-based compensation rose 19% to $250K from warrant vesting. Cash dwindled to $839 by quarter-end, with $326K used in operations offset by $321K in financing from $86K stock sales and $150K subscription collections; related-party debt stands at $547K alongside $49K shareholder notes at 8%. No free cash flow disclosed in the 10-Q. Progress continues on RetinalCam and IRB studies for macular degeneration, eyeing multistate expansion in September 2025. Yet funding remains precarious, with cash lasting mere days without fresh capital.
10-Q
Q1 FY2025 results
RetinalGenix narrowed its Q1 FY2025 net loss to $587K from $2.1M a year earlier, thanks to a sharp drop in stock-based compensation from $1.7M to $232K, while general and administrative expenses ticked up 4% to $341K and research and development plunged 84% to $13K amid funding constraints. Cash burn eased slightly to $187K used in operations, leaving $3.7K on hand after collecting a $150K stock subscription, but the company relies heavily on related-party advances totaling $684K due. Shareholders' notes payable of $49K carry 8% interest through December 2025. No revenues yet, as devices advance toward FDA clearance. Cash won't last long. Internal controls falter from poor segregation of duties.
10-K
FY2024 results
RetinalGenix Technologies posted a $4.3 million net loss for FY2024 ended December 31, 2024, up 107% y/y from $2.1 million, driven by $2.6 million in stock-based compensation from warrant grants while R&D expenses dipped 29% to $373,000 amid funding constraints that slowed engineering and prototyping. Q4 saw blood draws commence for the Pearl IRB study on anti-VEGF treatments for wet AMD, marking initial momentum in pharmacogenetic mapping integration post-2022 DNA/GPS acquisition, though no revenue emerged as devices like RetinalCam remain pre-launch. Cash dwindled to $6,000 by year-end, with $1.5 million in liabilities mostly to affiliates, underscoring urgent need for $6 million more to fund FDA clearance for RetinalGeniX and RetinalCam rollout by Q4 2025. No dividends or buybacks occurred; capex stayed minimal. Uncertainty in drug price negotiations under the new administration poses risks to future therapeutic pipelines.
8-K
Warrant exercise delayed
RetinalGenix Technologies amended a pre-funded warrant on February 19, 2025, delaying exercise of 28,014,540 common stock shares held by Sanovas Ophthalmology until the earlier of February 1, 2030, or three years post-uplisting to Nasdaq or NYSE American. This locks in potential dilution, signaling commitment to uplisting goals. No financial impact disclosed. Warrants stay dormant longer.
AMIX
Autonomix Medical, Inc.
0.63-0.03
INGN
Inogen, Inc
6.81-0.02
IRIX
IRIDEX Corporation
1.00+0.02
IRME
IR-Med Inc.
0.02-0.01
LNSR
LENSAR, Inc.
12.06+0.54
NXL
Nexalin Technology, Inc.
0.81-0.01
RGNX
REGENXBIO Inc.
14.11+0.28
RMTG
Regenerative Medical Technology
0.04+0.00
RXST
RxSight, Inc.
12.76+0.24
SGHT
Sight Sciences, Inc.
8.39+0.08